881392-78-5

Basic information

• Product Name: 2-amino-4-methyl-4-phenyl-pentanoic acid
• Synonyms: 2-amino-4-methyl-4-phenyl-pentanoic acid
• CAS NO: 881392-78-5
• Molecular Weight: 207.272
• Mol File: 881392-78-5.mol
• Article Data: 7

Chemical Properties

• CAS DataBase Reference: 2-amino-4-methyl-4-phenyl-pentanoic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 2-amino-4-methyl-4-phenyl-pentanoic acid(881392-78-5)
• EPA Substance Registry System: 2-amino-4-methyl-4-phenyl-pentanoic acid(881392-78-5)

Safety Data

• Hazardous Substances Data: 881392-78-5(Hazardous Substances Data)

Usage

Chemical compound

2-amino-4-methyl-4-phenyl-pentanoic acid

Additional groups

methyl and phenyl attached to carbon chain
Potential therapeutic properties in pharmaceutical and medicinal chemistry
Structural similarity to valine
Need for further research and clinical studies to understand biological functions and potential medical uses

Upstream product

• 66622-39-7 4-methyl-4-phenylpent-1ene 
• 6325-41-3 3-methyl-3-phenylbutanal 

Relevant articles and documents

FACTOR XIIA INHIBITORS

This invention relates to compoundsof formula (I)and methods of treatment using the compounds. The invention also relates to processes and methods for producing the compounds of the invention. The compounds of the invention are modulators of Factor XII (e.g. Factor XIIa). In particular, the compounds are inhibitors of Factor XIIa and may be useful as anticoagulants.

PROCESSES AND INTERMEDIATES FOR PREPARING CYSTEINE PROTEASE INHIBITORS

The present invention is directed to a novel process for preparing certain cysteine protease inhibitors.

HALOALKYL CONTAINING COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS

The present invention is directed to compounds that are inhibitors of cysteine proteases, in particular, cathepsins B, K, L, F, and S and are therefore useful in treating diseases mediated by these proteases. The present invention is directed to pharmaceutical compositions comprising these compounds and processes for preparing them.